Concepedia

Author

Rinat Yerushalmi

Rabin Medical CenterORCID

Also Known As

R Yerushalmi, R. Yerushalmi, R., Yerushalmi, RINAT YERUSHALMI, Rinat Yerushalmi, Rinat yerushalmi

202

Publications

9.3K

Citations

31

H-Index

68

Concepts

All Affiliations

Rabin Medical CenterTel Aviv UniversityBC Cancer AgencyTexas OncologyThe University of Texas MD Anderson Cancer Center
RY

About

Rinat Yerushalmi is an author at Rabin Medical Center specializing in medicine, breast cancer, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

17

26

2K

2

Health Sciences

9

9

254

3

Public Health

3

3

43

4

Allergy

1

1

33

5

Biostatistics

1

1

88

Rinat Yerushalmi

×

56

Publications

7.6K

Citations

28

H-Index

YearCitations

Metastatic Behavior of Breast Cancer Subtypes

Hagen F. Kennecke, Rinat Yerushalmi, Ryan Woods,

Journal of Clinical Oncology

2010

2.2K

Talazoparib in Patients with Advanced Breast Cancer and a Germline <i>BRCA</i> Mutation

Jennifer K. Litton, Hope S. Rugo, Johannes Ettl,

New England Journal of Medicine

2018

2K

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

Karen A. Gelmon, Marc Tischkowitz, Helen Mackay,

The Lancet Oncology

2011

1.1K

Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial

Jennifer K. Litton, Sara A. Hurvitz, Lida A. Mina,

Annals of Oncology

2020

372

Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes

Rinat Yerushalmi, Karen A. Gelmon, Samuel Leung,

Breast Cancer Research and Treatment

2011

135

Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial

Johannes Ettl, Ruben G.W. Quek, Ki Hoon Lee,

Annals of Oncology

2018

135

Prognostic impact of HER2-low expression in hormone receptor positive early breast cancer

Raz Mutai, Tamar Barkan, Assaf Moore,

The Breast

2021

132

Does multicentric/multifocal breast cancer differ from unifocal breast cancer? An analysis of survival and contralateral breast cancer incidence

Rinat Yerushalmi, Hagen F. Kennecke, Ryan Woods,

Breast Cancer Research and Treatment

2008

88

Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines

Orit Uziel, Eyal Fenig, Jardena Nordenberg,

British Journal of Cancer

2005

78

Chemotherapy-Induced Ovarian Failure as a Prototype for Acute Vascular Toxicity

Irit Ben‐Aharon, Israel Meizner, Tal Granot,

The Oncologist

2012

66

Page 1